UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 7,386	$ 10,369
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	495	526
Amortization	4,875	4,512
Provision for (recovery of) losses on accounts receivable	(4)	(2)
Amortization of Right of Use Assets	29	29
(Gain) loss on disposal of assets	1	0
Deferred income taxes	(20)	(398)
Stock-based compensation expense	121	85
Tax benefit attributable to exercise of stock options	7	20
Changes in operating assets and liabilities:
Accounts receivable and other receivables	442	(1,139)
Inventories	757	(1,449)
Prepaid expenses and other current assets	58	73
Accounts payable	(439)	(188)
Accrued expenses	651	(1,023)
Total adjustments	6,973	1,046
Net cash provided by operating activities	14,359	11,415
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment	(806)	(252)
Intangible assets	0	(21,000)
Net cash used in investing activities	(806)	(21,252)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	282	223
Common stock purchased and retired	(6,977)	(398)
Payment of dividends	(3,097)	(3,083)
Net cash used in financing activities	(9,792)	(3,258)
Effect of exchange rate changes on cash	(254)	(624)
Net decrease in cash and cash equivalents	3,507	(13,719)
Cash at beginning of period	42,787	51,112
Cash at end of period	46,294	37,393
Cash paid during the period for income taxes	2,153	3,957
Cash paid during the period for interest	$ 0	$ 0